EUVIMEDEUVIMED entdecken
Crossref

L26/P-076 Can microfluidic sperm selection (MFSS) enhance clinical ICSI outcome when applied to suboptimal semen specimens?

S. Bains, P. Xie, S. Cheung, L. Ng, A. De Jesus, O. Kocur, Z. Rosenwaks, G.D. Palermo

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Bains und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Can severe oligo-astheno-zoospermic specimens be processed by microfluidic sperm selection (MFSS) to ameliorate clinical outcome, and to what extent? Summary answer Protocol modifications allowed MFSS processing of suboptimal specimens, yielding improved sperm genomic integrity that resulted in higher embryo developmental competence and pregnancies. What is known already Intracytoplasmic sperm injection (ICSI) enables fertilization using a single spermatozoon regardless of semen parameters. Nevertheless, some couples fail to achieve the a successful pregnancy despite adequate semen parameters, implying a subtle male factor such as sperm chromatin fragmentation (SCF) and a compromised embryo developmental competence. Although MFSS has been clinically proven to enhance highly motile spermatozoa with higher genomic integrity, it can only be applied per protocol to semen samples with adequate parameters. Here we investigate the adoption of MFSS in oligo-astheno-zoospermic samples. Study design, size, duration In the past 7 years, we have included 335 patients undergoing MFSS for ICSI, allocated into MFSS-Adequate (241 patients, 357 samples, 5.2-172x106/ml concentration, 9-56% motility), MFSS-Oligozoospermic (55 patients, 60 samples,1.1-5x106/mL concentration, 5-49% motility) and MFSS-Severe Oligozoospermic (39 patients, 47 samples, 0.0004-1x106/mL concentration, 5-50% motility). In a cohort of patients, SCF (n = 211), chromosomal aneuploidy (n = 4), and gene studies (n = 5) were performed pre- and post-MFSS. Oligo-astheno-zoospermic samples (n = 464), processed by density gradient centrifugation (DGC), served as controls. Participants/materials, setting, methods The study group included couples with a paternal age of 37.5±4 years and a maternal age of 35.9±5 years. Specimens processed by MFSS with a modified protocol were categorized by semen quality (adequate, oligozoospermic, severe oligozoospermic). SCF was assessed by TUNEL, aneuploidy by FISH, and gene mutations by whole-exome sequencing pre- and post-MFSS. Fertilization, clinical pregnancy rate (CPR), and ongoing/delivery outcomes were compared across groups. Main results and the role of chance The MFSS-Adequate group had a semen volume of 2.3±1ml, concentration of 48.6±37x106/ml, motility of 32.6±22%, normal morphology of 2.5±2% and SCF of 18.9±6%. Following MFSS, motility increased (97.5±3%, P<0.001) and SCF decreased (2.3±2%, P<0.001). In the MFSS-Oligozoospermic group, semen parameters were as follows: 2.5±2ml volume, 3.4±1x106/ml concentration, 29.6±13% motility, 1.8±1% normal morphology, and 22.3±7% SCF. MFSS enhanced motility (97.6±4%, P<0.001) and lowered SCF (3.0±3%, P<0.01). In severe oligozoospermia, MFSS improved motility (29.3±19% vs 94.6±15%, P<0.01) and morphology (0.7±1% vs 2.0±1%, P<0.01), reducing SCF (3.1±3%, P<0.01) Interestingly, sperm aneuploidy decreased after MFSS (2.2% vs. 2.8%). Even more surprising, whole-exome sequencing identified 572 gene mutations among >40,000 genes, whereas MFSS reduced mutations to 47 genes (P<0.0001). Clinically, DGC yielded fertilization rate of 74.5% (3086/4142), CPR of 40.2% (159/396) and eventual ongoing/delivery rate of 36.1% (143/396). MFSS-Adequate group achieved a comparable fertilization rate (77.4%, 2466/3230), a higher CPR (48.8%, 109/223, P<0.01) and ongoing/delivery rate (45.9%, 102/223, P<0.01). The MFSS-Oligozoospermic group yielded a similar fertilization rate (77.6%, 493/635) and CPR (48.3%, 29/60), but a higher ongoing/delivery rate (46.7%, 28/60, P<0.05). Even in the severe oligozoospermic couples, MFSS demonstrated satisfactory fertilization (73.3%, 344/469) with favorable CPR (46.9%, 22/47) and delivery rate (44.7%, 21/47). Limitations, reasons for caution This is an observational study with a relatively small sample size. Nonetheless, protocol modifications allowed a successful adoption of MFSS on oligo-astheno-zoospermic samples, yielding satisfactory clinical outcome. Wider implications of the findings MFSS was confirmed to be a valid approach to select highly motile, morphologically normal, and genetically competent spermatozoa. By adjusting the preparation technique, MFSS application proved beneficial in yielding satisfactory fertilization and pregnancy rates, even in severe oligo-astheno-zoospermic men. Trial registration number No

Zitieren

APA

Bains, S., Xie, P., Cheung, S., Ng, L., Jesus, A. D., Kocur, O., Rosenwaks, Z., & Palermo, G. (2026). L26/P-076 Can microfluidic sperm selection (MFSS) enhance clinical ICSI outcome when applied to suboptimal semen specimens?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.412

Vancouver

Bains S, Xie P, Cheung S, Ng L, Jesus AD, Kocur O, et al. L26/P-076 Can microfluidic sperm selection (MFSS) enhance clinical ICSI outcome when applied to suboptimal semen specimens?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.412

BibTeX
@article{Bains2026,
  author = {Bains, S. and Xie, P. and Cheung, S. and Ng, L. and Jesus, A. De and Kocur, O. and Rosenwaks, Z. and Palermo, G.D.},
  title = {L26/P-076 Can microfluidic sperm selection (MFSS) enhance clinical ICSI outcome when applied to suboptimal semen specimens?},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.412}
}
Kostenlos starten →